A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer

Eligibility

Inclusion Criteria

* Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
* Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
* In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.

Exclusion Criteria

* Participants must not have any untreated CNS metastases.
* Participants must not have an active, known or suspected autoimmune disease.
* Participants must not have had a prior organ or tissue allograft.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Conditions3

Interventions2

Locations5 sites

Find trials near these locations

Related trials

• A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study — LaNova Medicines Zhejiang Co., Ltd.
• A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) — Daniel Morgenstern
• A Study of BND-35 in Participants With Advanced Solid Tumors — Biond Biologics
• A Study of TRK-950 in Patients With Advanced Solid Tumors — Toray Industries, Inc
• A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma — University Health Network, Toronto
• A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors — Suzhou Transcenta Therapeutics Co., Ltd.
• Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma — Gustave Roussy, Cancer Campus, Grand Paris
• Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients — Sheba Medical Center

Browse More Trials